Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate Update

WILMINGTON, Del., May 14, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced that...
May 11, 2026 16:05 ET | Source: Harrow, Inc.

Harrow Announces First Quarter 2026 Financial Results

First Quarter 2026 and Selected Highlights: VEVYE® delivered record new and total prescription performance (despite an approximate 18% decline in the overall branded dry eye category)VEVYE demand...
May 07, 2026 08:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and Suicidality

Preliminary research suggests that D-cycloserine significantly enhances the effect of Transcranial Magnetic Stimulation (TMS) Trial is planned to be conducted at a leading US academic teaching...
May 05, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free Ketamine

NRXP is manufacturing and commercializing preservative free ketamine.
April 30, 2026 06:02 ET | Source: AH Realty Trust

AH Realty Trust Advances Board Refreshment Process to Support Ongoing Strategic Transformation

Nominates Theodore Bigman and Lori Wittman to Stand for Election as New Independent Directors at 2026 Annual Meeting Dennis Gartman and George Allen Plan to Retire from the Board F. Blair...
April 22, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine Program

NRx has received a positive review letter (Discipline Review Letter) addressing Drug Quality requesting only “Minor” administrative changesNRx conducted a meeting with leadership of the FDA Office of...
April 20, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and Suicidality

President Trump signed an Executive Order: ACCELERATING MEDICAL TREATMENTS FOR SERIOUS MENTAL ILLNESS on April 18, 2026.The order directs acceleration of research and lowered barriers to approvals of...
April 15, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with Neuroplastic Therapy for Military and First Responder Applications

Dr. Dennis K. McBride, PhD (CAPT, Medical Service Corps, US Navy, Ret., Distinguished Research Fellow, National Defense University, and former senior executive, Office Secretary of Defense) to serve...
April 13, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces Appointment of Glenn Tyson as the Company’s first Chief Commercial Officer

Mr Tyson has both clinical experience treating patients with serious mental health disorders and 25 years of successful industry commercial experience in the development and sales of medications in...
April 06, 2026 07:00 ET | Source: NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application

NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory...